Amodiaquine-induced hepatitis. A report of seven cases.
Seven patients developed hepatitis after receiving amodiaquine for malaria prophylaxis for 4 to 15 weeks. Four patients had a minor form of hepatitis: jaundice was mild or absent, serum aminotransferase levels were moderately increased, and recovery was prompt. Three patients had a severe form: jaundice was intense, serum aminotransferase levels were markedly increased, jaundice persisted for 3 to 6 months, and liver tests were still abnormal 7 to 27 months after the onset of hepatitis. In two patients, serum aminotransferase levels increased promptly after readministration of the drug, which is consistent with an immunoallergic mechanism for amodiaquine-induced hepatitis.
Larrey
D
D
Castot
A
A
Pëssayre
D
D
Merigot
P
P
Machayekhy
J P
JP
Feldmann
G
G
Lenoir
A
A
Rueff
B
B
Benhamou
J P
JP
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000655:Amodiaquine / Q000009:adverse effects*; D001219:Aspartate Aminotransferases / Q000097:blood; D001247:Asthenia / Q000209:etiology; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology*; D005260:Female; D006801:Humans; D008099:Liver / Q000473:pathology; D008288:Malaria / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D014839:Vomiting / Q000209:etiology; D005723:gamma-Glutamyltransferase / Q000097:blood
D000655:Amodiaquine; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase